Discounted Cash Flow
Genenta Science S.p.a. ADR
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2019 | — | $-5.3m | — | — | — |
| 2020 | — | $-6.5m (-21.6%) | $-7.0m | — | — |
| 2021 | — | $-6.4m (1.1%) | $-8.1m (-14.9%) | — | $-0.37 |
| 2022 | $0 | $-9.9m (-53.3%) | $-8.7m (-6.9%) | — | $-0.47 (-27.0%) |
| 2023 | $0 | $-13.5m (-37.4%) | $-13.0m (-50.7%) | — | $-0.64 (-36.2%) |
| 2024 | $0 | $-10.4m (23.5%) | $-7.3m (44.3%) | — | $-0.49 (23.4%) |
| 2025 | $0 | $-7.6m (26.7%) | $-8.0m (-10.1%) | — | $-0.33 (32.7%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
SEC filings report in EUR. Values above are converted to USD for comparison with the US-listed share price.
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.